Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

38%

8 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed with results

Key Signals

3 with results87% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (2)
Early P 1 (1)
P 1 (2)
P 2 (6)
P 3 (5)
P 4 (3)

Trial Status

Completed13
Recruiting2
Withdrawn2
Terminated2
Unknown2

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT05933525Phase 2Completed

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

NCT06363890RecruitingPrimary

Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia

NCT06556940Early Phase 1RecruitingPrimary

G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies

NCT02498301Not ApplicableCompletedPrimary

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT04027894Phase 2UnknownPrimary

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

NCT04026984Phase 2UnknownPrimary

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

NCT03866291Completed

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

NCT02920242Phase 3TerminatedPrimary

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

NCT01208922Phase 3CompletedPrimary

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

NCT03301103Not ApplicableCompletedPrimary

PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli

NCT01142089Phase 3CompletedPrimary

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

NCT02736539Phase 3WithdrawnPrimary

Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

NCT00564577Phase 1CompletedPrimary

Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17

NCT00564863Phase 1CompletedPrimary

Dose-Finding Study of CS19 Expressing ETEC Challenge Strains

NCT00524004Phase 2CompletedPrimary

Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD

NCT00875875Phase 4WithdrawnPrimary

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

NCT00672035Phase 2CompletedPrimary

Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

NCT01040325Phase 2CompletedPrimary

Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

NCT00993681Phase 3CompletedPrimary

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study

NCT01005849Phase 4TerminatedPrimary

Probiotics and the Prevention of Traveler's Diarrhea

Scroll to load more

Research Network

Activity Timeline